This Sarepta Therapeutics Analyst Begins Coverage On A Bearish Note; Here Are Top 5 Initiations For Monday

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page.

Exane BNP Paribas analyst Kevin Grundy initiated coverage on Constellation Brands, Inc. (NYSE:STZ) with a Neutral rating and announced a price target of $261. Constellation Brands shares closed at $239.66 on Friday. See how other analysts view this stock.
TD Cowen analyst Joseph Thome initiated coverage on Viridian Therapeutics, Inc. (NASDAQ:VRDN) with a Buy rating. Viridian Therapeutics shares closed at $20.20 on Friday. See how other analysts view this stock.
Canaccord Genuity analyst Edward Nash initiated coverage on Apogee Therapeutics, Inc. (NASDAQ:APGE) with a Buy rating and announced a price target of $89. Apogee Therapeutics shares closed at $43.46 on Friday. See how other analysts view this stock.
UBS analyst Timothy Arcuri initiated coverage on Arm Holdings plc (NASDAQ:ARM) with a Buy rating and announced a price target of $160. ARM shares closed at $135.99 on Friday. See how other analysts view this stock.
HC Wainwright & Co. analyst Mitchell Kapoor initiated coverage on Sarepta Therapeutics, Inc. (NASDAQ:SRPT) with a Sell rating and announced a price target of $80. Sarepta Therapeutics shares closed at $114.23 on Friday. See how other analysts view this stock.